Travere Therapeutics Inc
$ 42.13
37.23%
14 Apr - close price
- Market Cap 2,831,816,000 USD
- Current Price $ 42.13
- High / Low $ 43.31 / 39.90
- Stock P/E N/A
- Book Value 1.26
- EPS -0.57
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.07 %
- ROE -0.58 %
- 52 Week High 43.30
- 52 Week Low 13.88
About
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
Analyst Target Price
$42.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-19 | 2025-10-30 | 2025-07-30 | 2025-05-05 | 2025-02-13 | 2024-10-31 | 2024-08-01 | 2024-05-06 | 2024-03-12 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | 0.37 | 0.59 | 0.13 | -0.19 | -0.47 | -0.7 | -0.91 | -1.76 | -1.18 | -1.17 | -1.13 | -1.27 |
| Estimated EPS | -0.04 | -0.29 | -0.2715 | -0.3943 | -0.3786 | -0.68 | -0.86 | -0.99 | -1.27 | -0.14 | -1.16 | -1.17 |
| Surprise | 0.41 | 0.88 | 0.4015 | 0.2043 | -0.0914 | -0.02 | -0.05 | -0.77 | 0.09 | -1.03 | 0.03 | -0.1 |
| Surprise Percentage | 1025% | 303.4483% | 147.8821% | 51.8133% | -24.1416% | -2.9412% | -5.814% | -77.7778% | 7.0866% | -735.7143% | 2.5862% | -8.547% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.28 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TVTX
2026-04-14 20:10:08
This SEC Form 144 filing by Travere Therapeutics, Inc. details the proposed sale of 8,000 shares of common stock with an aggregate market value of $245,600.00. The securities were acquired on April 14, 2026, through the exercise of stock options from the Issuer, with payment made in cash. The filing indicates a neutral impact and sentiment regarding the transaction.
2026-04-14 14:10:08
U.S. stocks moved higher on Tuesday with the Dow Jones gaining over 200 points. Several companies experienced significant gains due to various corporate announcements. Avanos Medical surged 69% after a going-private deal, while Travere Therapeutics gained 33.6% following FDA approval for its drug FILSPARI. Globalstar jumped 9.6% after announcing a merger agreement with Amazon.com, Inc.
2026-04-14 10:05:14
The FDA has granted full approval to Travere Therapeutics' FILSPARI (sparsentan) for reducing proteinuria in adults and children aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This approval makes FILSPARI the first and only FDA-approved medication specifically for FSGS, expanding its indication beyond IgA nephropathy and targeting an estimated U.S. population of over 30,000 patients. Clinical trials demonstrated FILSPARI's significant efficacy in proteinuria reduction and a comparable safety profile to irbesartan.
2026-04-14 07:09:14
Travere Therapeutics received full FDA approval for FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first FDA-approved medicine for FSGS, expanding its indication beyond IgA nephropathy and potentially reaching over 30,000 U.S. patients with FSGS and over 100,000 combined FSGS and IgAN patients. Clinical trials, particularly the Phase 3 DUPLEX Study, demonstrated significant proteinuria reduction and improved eGFR in patients treated with FILSPARI compared to irbesartan, with a safety profile consistent across programs.
2026-04-14 06:09:14
Travere Therapeutics (TVTX) has received FDA approval for its drug Filspari, making it the first FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) in patients aged 8 and older. This approval is based on data showing a 48% reduction in proteinuria for FSGS patients treated with Filspari. The drug was previously approved for IgA nephropathy, and this recent decision follows an earlier delay by the FDA.
2026-04-14 05:09:14
Travere Therapeutics (TVTX) has received FDA approval for FILSPARI, a treatment for focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome. This marks the first and only FDA-sanctioned medication for this condition, targeting over 30,000 potential U.S. patients. Despite this significant development, the company faces challenges in financial strength and profitability, with notable insider selling activities.
